Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4.
about
Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 inductionMongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's diseaseRole of regulatory T cell in the pathogenesis of inflammatory bowel diseaseAnimal models to study acute and chronic intestinal inflammation in mammalsA review on chemical-induced inflammatory bowel disease models in rodentsAssociation among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel diseaseInterleukin 13 and serotonin: linking the immune and endocrine systems in murine models of intestinal inflammationImpacts of cigarette smoking on immune responsiveness: Up and down or upside down?Production of MDC/CCL22 by human intestinal epithelial cellsBlocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel diseaseInduction of colonic regulatory T cells by indigenous Clostridium speciesInflammatory bowel diseaseThe NLRP12 Sensor Negatively Regulates Autoinflammatory Disease by Modulating Interleukin-4 Production in T Cells.The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitisImmune therapy in inflammatory bowel disease and models of colitis.A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesisUncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?Colitis in transgenic and knockout animals as models of human inflammatory bowel disease.CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice.Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection.Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation.Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease?Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.Immunopathology of intestinal helminth infection.The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease.Deficiency in expression of the signaling protein Sin/Efs leads to T-lymphocyte activation and mucosal inflammation.Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.Modulating the intestinal immune system: the role of lymphotoxin and GALT organs.Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.Interactions between the intestinal microbiota and innate lymphoid cells.Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient miceImmunotherapeutic approaches to inflammatory bowel diseases.Clinical aspects and pathophysiology of inflammatory bowel disease.Cytokine-induced alterations of α7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis.Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages.An important regulatory role for CD4+CD8 alpha alpha T cells in the intestinal epithelial layer in the prevention of inflammatory bowel diseaseColon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism.Immune networks in animal models of inflammatory bowel disease.
P2860
Q24610206-AE50B177-D638-4AAC-BDE6-059FC145DBE5Q24676238-A718BB9D-DFEC-4D7E-A129-53FCF8671EB3Q26745717-0ED5F10D-1CEC-4F19-AE20-DBF1E2F8C889Q26768560-DA7C4224-49A3-4CD4-9A99-A54563349CB0Q26777430-7A3C22C3-AE81-428C-9459-81082CF549AEQ26827500-975A5BBA-A689-4943-B594-7BAE93AD79FDQ27006589-734BAB03-0113-4B4D-97B7-D99F1E8ECB7BQ27308772-CA5470FF-1DD5-40E7-9153-0D755424F14AQ28072341-948C9EA5-0FFE-4E0F-88CA-4D8A2E475C7DQ28188916-5F217300-DB4C-4906-B384-DF4B5399E606Q28346591-FB9D1BED-3E05-4735-952F-D672FD8C873DQ29547701-97BCFD64-C1B9-4AF1-949C-9FB9D7A12C5BQ29615500-A5CC6CA3-F7DD-4BFF-859D-9529FD3A2E16Q30300172-143393F7-BC48-4654-9152-53494CCEBCF5Q30483252-459CD265-F62B-43EC-852D-C48EA106182FQ30774968-CD9B92E3-DFFB-4A44-9841-102299D60138Q33597235-E494CDE2-12E9-4D2E-B21F-A49EC7A83D9EQ33711741-77B29DBB-45CC-453A-BB83-8D4E416C9E4EQ33713331-AE096BFD-FCF2-4C4F-A9EE-01AD5154AE03Q33769231-7E66BCA5-7D8C-4B23-B8A1-DF9F382D69D3Q33852941-AAC1423D-C29F-472E-9E08-5FF4230BE764Q33886458-06EB91DF-77EE-4304-8F7C-5F9BC5903D45Q33945974-FFB364C1-63D6-4E55-BC31-91A11F0EE80AQ33949335-6A659A50-858E-46DE-8E90-5638FF98B846Q34084499-93379485-66CB-4181-8904-5979AA59B075Q34109364-CFD608EF-1EE5-4A01-A25B-1968288424A7Q34187186-25847910-7539-4F93-92F9-C5B8C6F1E5C3Q34230864-0845C977-C26A-4EE3-BBE8-233A93C8293EQ34233126-EAA3BF4F-422D-4106-AFEA-58111714DAF0Q34298341-A4288CCF-F253-4EE9-AEBC-1BD0C46AA35AQ34321127-88DFD4FF-7EDE-458D-B14D-F989F7B6545BQ34397537-211790B3-1C05-47B2-B033-F4CFA8A5E7ADQ34430392-85A54BE0-CBEA-44D5-AA09-D754DF347C77Q34451989-765029AA-1A9B-47BF-BA00-99DCEA8B41C6Q34487217-89177D8D-4842-43BA-80BF-2E1114EBB6ABQ34662156-F0590E6D-92B9-411B-ABA1-FEFEB81BED0EQ34876594-F7BD84A8-20C3-4F15-96AD-7140E6A0A2CDQ34982863-DEF51032-45C0-4D43-BD1F-3486195D1878Q35015672-F79AA9BA-0A77-4E37-AD73-DFEA790B1A42Q35193871-8E26B315-42B9-42C3-9383-422BDFF622CC
P2860
Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@ast
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@en
type
label
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@ast
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@en
prefLabel
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@ast
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@en
P2093
P2860
P356
P1476
Oxazolone colitis: A murine mo ...... h antibodies to interleukin 4.
@en
P2093
P2860
P304
P356
10.1084/JEM.188.10.1929
P407
P577
1998-11-01T00:00:00Z